

RECEIVED

JAN 14 2016



Lou Dallago
Vice President – US Trade Group

Pfizer Inc
235 East 42nd Street, New York, NY 10017

URGENT: DRUG RECALL

January 11, 2016



LYRICA® (pregabalin) Capsules, CV

NDC	Lot Number	Expiration Date	Strength	Configuration/Count
0071-1013-68	M07861	05/2018	50 mg	Bottle of 90 capsules
0071-1014-68	M07862	05/2018	75 mg	Bottle of 90 capsules
0071-1014-68	M07865	06/2018	75 mg	Bottle of 90 capsules

Dear Customer:

Pfizer Inc is voluntarily recalling the above referenced lots of LYRICA® (pregabalin) Capsules, CV due to the potential presence of deformed or damaged capsules. Please note that use of, or exposure to, product from these lots is not likely to cause adverse health consequences.

FEDERAL REGULATION 21 CFR 7.49 (d) RESPONSIBILITY OF RECIPIENT STATES: "CONSIGNEES THAT RECEIVE A RECALL COMMUNICATION SHOULD IMMEDIATELY CARRY OUT THE INSTRUCTIONS SET FORTH BY THE RECALLING FIRM ..." PFIZER INC RECOMMENDS THAT YOU RESPOND TO THIS RECALL, EVEN IF YOU DO NOT HAVE THE RECALLED PRODUCT. TO RESPOND, COMPLETE THE REQUESTED INFORMATION ON THE ENCLOSED POSTAGE-PAID, BUSINESS REPLY CARD (BRC) AND RETURN IT TO US, AS DIRECTED, WITHIN FIVE (5) BUSINESS DAYS. If you have any questions about responding to this letter, please contact Stericycle Inc. at 1-800-805-3093 (Mon.-Fri. 8 am-5 pm EST).

The recall of the above referenced lots of LYRICA® (pregabalin) Capsules, CV is being conducted to the Retail Level.



Our records indicate that you may have received shipment of one or more of the affected lots between September 2015 and October 2015. Please check your stock immediately against the table above. If you have any of the affected product in your inventory, please stop distribution immediately and promptly return it to Stericycle Inc.; 2670 Executive Drive, Suite A; Indianapolis, IN 46241; Attn: Event 4773 using the enclosed pre-paid UPS label. If you received this notification without the prepaid UPS label and BRC, require additional shipping labels, or have questions regarding the return procedure, please contact Stericycle Inc. at 1-800-805-3093.

If you have further distributed any of these lots to other wholesale and/ or retail level accounts, please conduct a sub-recall to those accounts and communicate this recall information immediately. Please request that they immediately cease distribution of the affected lots and promptly return the product directly to the above Stericycle Inc. address. Your accounts do not need to fill out a BRC; however, if they have inventory of the affected product, they can contact Stericycle Inc. at 1-800-805-3093 to obtain pre-paid shipping labels for product returns. Further authorization is not required for product returns.

Reimbursement for the returned product will be made by credit memorandum. If you have any questions regarding the reimbursement, please contact your Pfizer Customer Service Representative at 1-800-533-4535 (Mon.-Fri. 8 am-5:30pm EST).

If you received free product through the Pfizer RxPathways[®]™ program between September 2015 and October 2015, and still have any of this inventory in stock, please follow the instructions above for returning the product to Stericycle Inc. Pfizer Customer Service will replace the returned product with new inventory.

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration. We appreciate your immediate attention and cooperation, and sincerely regret any inconvenience this action may cause you. If you have any medical information questions regarding the product, please contact Pfizer Medical Information at 1-800-438-1985 (Mon.-Thu. 9 am-8 pm EST or Fri. 9 am-5 pm EST).

Sincerely,

A handwritten signature in black ink, appearing to read "L. Dallago", with a long horizontal flourish extending to the right.

Lou Dallago
Vice President U.S. Trade Group